ArticleJugan geon-gang gwa jilbyeong2025
[Review of the Global Burden of Tuberculosis in 2023: Insights from the WHO Global Tuberculosis Report 2024].
Article in Jugan geon-gang gwa jilbyeong, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and contributing factors of drug-resistant tuberculosis (DR-TB) in iran: a systematic review.BMC infectious diseases · 2025Pooled it
- Identification of mitochondrial metabolism-associated tuberculosis key genes and construction of a diagnostic model based on WGCNA.Medical microbiology and immunology · 2026Article
- Glucagon-like Peptide-1 Receptor Agonists and Risk of Tuberculosis in Type 2 Diabetes.Nature communications · 2026Article
- Infection dose shapes granuloma phenotypes in a humanized mouse model of tuberculosis.Research square · 2026Article
- Current research progress on extracellular vesicles derived from mesenchymal stem cells in tuberculosis treatment (Review).Molecular medicine reports · 2026Review
- Healthcare system preparedness as a mediating factor in climate-driven tuberculosis outcomes: an ecological study.BMC health services research · 2026Article
- Drug-Resistant Tuberculous Spondylitis Treated with Bedaquiline-Containing Regimens in South Korea: Two Case Reports.Antibiotics (Basel, Switzerland) · 2026Article
- Clinical epidemiology and risk prediction of unsuccessful treatment outcomes in pulmonary tuberculosis with diabetes mellitus.BMC medicine · 2026Article
- A detailed analysis of borderline results in the QuantiFERON-TB Gold-Plus assay incorporating longitudinal follow-up: intermediate-burden setting.Microbiology spectrum · 2026Article
- Knowledge, health-seeking behavior, and predictors of treatment adherence among tuberculosis patients in the North-West Region of Cameroon.The Pan African medical journal · 2026Article
- Operational Overview and Implementation Challenges of Misokkumteo, a National Tuberculosis Care Facility (2011-2024).Public health weekly report · 2026Review
- [Commemoration of the Special Issue on Tuberculosis in "Jugan geon-gang gwa jilbyeong · 2025Article
- Cohort profile: the KDCA-Tuberculosis-NHIS cohort linking tuberculosis surveillance and health insurance data in Korea.Epidemiology and health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Tuberculosis (TB), caused by the airborne Methods: This report refers to a writing extracted the Global Tuberculosis Report 2024 and analyzed using data downloaded from the World Health Organization (WHO) website. Results: In 2023, the global TB incidence reached 10.8 million (134 cases per 100,000), and a 0.9% increase from 10.7 million in 2022. TB deaths decreased by 5.3%, falling to 1.25 million from 1.32 million the previous year. The ROK reported a TB incidence rate of 38 cases per 100,000 population and a mortality rate of 3 people per 100,000 population in 2023. Among the 38 OECD member countries, the ROK ranked second in TB incidence and fifth in TB mortality. Conclusions: In the WHO's End TB strategy, which targets a 50% reduction in TB incidence and a 75% reduction in TB deaths by 2025 (relative to 2015 levels), the ROK has achieved a 51.9% reduction in TB incidence and a 44.4% reduction in TB deaths by 2023. The ROK enters the aging population, and has increased TB incidence aged 65 or older. So, it is essential to strengthen TB policies focused on early detection, timely-treatment and management continuously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.